ADGRG1 and acute myeloid leukemia: Given that PIP/56 treatment did not affect murine or human BM cells but suppressed the growth of EVI1high AML cells, GPR56-specific PIP may represent a promising drug for eliminating EVI1high AML cells with no adverse effects on hematopoietic cells.